Hutchmed (China) Limited (HCM) ORD USD0.10

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
Hutchmed to get milestone payment after China drug approval
30 June 2025 12:29
(Sharecast News) - Hutchmed announced on Monday that China's National Medical Products Administration (NMPA) has approved the new drug application for the combination of 'Orpathys'. Or...
-
Hutchmed new drug application accepted in China
5 June 2025 11:18
(Sharecast News) - Hutchmed China and Innovent Biologics announced on Thursday that China's National Medical Products Administration had accepted a new drug application for a combination therapy using...
-
Hutchmed China upbeat on results from lung cancer trial
2 June 2025 10:04
(Sharecast News) - Hutchmed China reported positive interim results from its phase three 'SACHI' trial on Monday, showing that the combination of savolitinib and osimertinib significantly improved...
-
Hutchmed enrols patients for phase two savolitinib trial
22 April 2025 08:46
(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for the registration phase of its phase two clinical trial, evaluating savolitinib in Chinese patients with...
-
Hutchmed renal cell carcinoma trial meets primary endpoint
19 March 2025 10:55
(Sharecast News) - Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial evaluating the combination of fruquintinib and sintilimab as a...
-
Hutchmed announces progress, hits milestone with lung cancer treatment
2 January 2025 15:30
(Sharecast News) - Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment and a substantial divestment aimed at bolstering its core...
-
Hutchmed to receive $10m milestone payment from partner Takeda
13 December 2024 09:36
(Sharecast News) - Hutchmed China announced on Friday that it would receive a $10m milestone payment from its partner Takeda, following a national reimbursement recommendation for 'Fruzaqla', or...
-
Hutchmed lung cancer therapy gets breakthrough designation in China
12 December 2024 11:27
(Sharecast News) - Hutchmed China announced on Thursday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD)...
-
Hutchmed endometrial cancer treatment gets conditional approval in China
3 December 2024 10:14
(Sharecast News) - Hutchmed China and its partner Innovent Biologics announced conditional approval from China's National Medical Products Administration (NMPA) for the combination of...
-
Hutchmed partner launches Fruzaqla in Japan
22 November 2024 11:54
(Sharecast News) - Hutchmed China announced the launch of 'Fruzaqla', or fruquintinib, in Japan on Friday by its partner, Takeda, following approval from Japan's Ministry of Health, Labour and...
-
Hutchmed to receive $20m Fruzaqla milestone payment
31 October 2024 11:04
(Sharecast News) - Hutchmed China announced on Thursday that it was set to receive a $20m milestone payment from its partner Takeda, after sales of 'Fruzaqla', or fruquintinib, surpassed $200m.
-
Hutchmed reports positive results from AstraZeneca lung cancer collaboration
16 October 2024 11:41
(Sharecast News) - Hutchmed China announced positive results from its Savannah phase two trial on Wednesday, which studied the combination of 'Tagrisso', or osimertinib, and 'Orpathys',...
Company announcements Announcements
-
HUTCHMED to Announce 2025 Half-Year Results
3 July 2025 09:30
HUTCHMED (China) Limited
-
Update on Joint Corporate Brokers in London
2 July 2025 10:00
HUTCHMED (China) Limited
-
Blocklisting Six Monthly Return
30 June 2025 09:30
HUTCHMED (China) Limited
-
Total Voting Rights
30 June 2025 09:30
HUTCHMED (China) Limited
-
China Approval based on Phase III SACHI Trial
30 June 2025 09:30
HUTCHMED (China) Limited
-
Grant of Share Options and Awards under LTIP
10 June 2025 11:00
HUTCHMED (China) Limited
-
HUTCHMED and Innovent Announce NDA Acceptance
5 June 2025 07:00
HUTCHMED (China) Limited
-
HUTCHMED Highlights SACHI Phase III Data at ASCO
2 June 2025 07:00
HUTCHMED (China) Limited
-
Total Voting Rights
30 May 2025 09:30
HUTCHMED (China) Limited
-
HUTCHMED Highlights Data to be Presented at ASCO
23 May 2025 07:00
HUTCHMED (China) Limited
-
AGM held on May 13, 2025 – Poll Results
13 May 2025 11:45
HUTCHMED (China) Limited
-
HUTCHMED - Data to be Presented at AACR 2025
24 April 2025 07:00
HUTCHMED (China) Limited
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.